# Xiaolu Biomedicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xiaolu-biomedicine

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Latest round: Angel (Apr 22, 2025)
- Investors on record: 8

## About

Based in Suzhou, China, and founded in 2025, Xiaolu Biomedicine operates as a biopharmaceuticals developer that focuses on the development of large molecule antibody drug. In April 2025, the company closed an angel funding co-led by new investors YuanBio Venture and Together To Miracle Capital. Other new investors Oriza Holdings, GL Ventures, Suzhou Capital Group, Shanghai Boquan Equity Investment Management, Beijing Biotechnology Science Park Venture Fund, Beijing Life Science Park Innovation Investment Fund, Hefei Industry Investment Group and other unspecified investors. Xiaolu Biomedicine focuses on the research and development of large molecule antibody drugs in the field of autoimmune and inflammatory diseases. The company has independently developed an antibody technology platform to develop a new generation of drugs by finding targets and target combinations based on pathogenic mechanisms. The company generates revenue by developing and providing innovative medicines for autoimmune and inflammatory diseases. The company will use the angel funding for the R&D and industrialization of its new generation of autoimmune and inflammatory drugs.

## Funding rounds

- Angel, Apr 22, 2025 — Oriza Holdings, YuanBio Venture, Hefei Industry Investment Group, GL Ventures, Shanghai Boquan Equity Investment Management, Beijing Life Science Park Innovation Investment Fund, Suzhou Capital Group, Together To Miracle

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- Hefei Industry Investment Group — Angel
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Angel
- Shanghai Boquan Equity Investment Management — Angel
- Beijing Life Science Park Innovation Investment Fund — Angel
- Suzhou Capital Group — Angel
- Together To Miracle — Angel